Manufacture of bulk drugs at the heart of what we do
India’s first company to start commercial production of Anti-tuberculosis drug Rifampicin
Gujarat Themis Biosyn Limited was incorporated in 1981 as a joint sector company with GIIC Ltd. and Chemosyn (P) Ltd. It commenced production in August 1985. It was subsequently taken over in June 1991 by Yuhan Group, South Korea and Pharmaceutical Business Group (India) Ltd. (PBG); a unique consortium of five competing drug companies - Themis Medicare Ltd., Kopran Ltd., Anant & Co., Cadila Health Care Ltd. (Zydus) and Lyka Labs Ltd. It is being actively managed by Themis Medicare Ltd. (JV company of Gedeon Richter Ltd, Hungary) since 2007.
News Corner
1. Gujarat Themis Biosyn Ltd. is pleased to announce operating income of Rs. 826.61 Lacs during the quarter ended 30th June, 2015 against Rs. 804.89 Lacs achieved during the quarter ended 31st March, 2015.
2. The net profit amounted to Rs. 122.60 Lacs during the quarter ended 30th June, 2015 against Rs. 84.66 Lacs recorded during the quarter ended 31st March, 2015.
3. The company has earned EPS (not annualized) of Rs. 0.84 per share of Rs. 5/- each against Rs. 0.58 for the quarter ended 31st March, 2015.
4. The net worth of the Company has become positive during the quarter ended 30th June, 2015 much ahead as envisaged in the Scheme of Rehabilitation approved by the BIFR. The approved scheme envisaged positive networth during the year 2018-19.
Annual Report 2016 – 2017